- Home
- EMO vs NRIX Comparison
EMO vs NRIX Comparison
Compare EMO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- NRIX
- Stock Information
- Founded
- EMO 2011
- NRIX 2009
- Country
- EMO United States
- NRIX United States
- Employees
- EMO N/A
- NRIX N/A
- Industry
- EMO Investment Managers
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- NRIX Health Care
- Exchange
- EMO Nasdaq
- NRIX Nasdaq
- Market Cap
- EMO 860.2M
- NRIX 766.0M
- IPO Year
- EMO N/A
- NRIX 2020
- Fundamental
- Price
- EMO $47.12
- NRIX $10.14
- Analyst Decision
- EMO
- NRIX Strong Buy
- Analyst Count
- EMO 0
- NRIX 15
- Target Price
- EMO N/A
- NRIX $29.13
- AVG Volume (30 Days)
- EMO 27.1K
- NRIX 721.5K
- Earning Date
- EMO 01-01-0001
- NRIX 10-10-2025
- Dividend Yield
- EMO 6.70%
- NRIX N/A
- EPS Growth
- EMO N/A
- NRIX N/A
- EPS
- EMO N/A
- NRIX N/A
- Revenue
- EMO N/A
- NRIX $88,381,000.00
- Revenue This Year
- EMO N/A
- NRIX $71.51
- Revenue Next Year
- EMO N/A
- NRIX N/A
- P/E Ratio
- EMO N/A
- NRIX N/A
- Revenue Growth
- EMO N/A
- NRIX 41.86
- 52 Week Low
- EMO $26.42
- NRIX $8.18
- 52 Week High
- EMO $40.17
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- EMO 46.72
- NRIX 43.01
- Support Level
- EMO $47.22
- NRIX $9.29
- Resistance Level
- EMO $48.50
- NRIX $10.78
- Average True Range (ATR)
- EMO 0.78
- NRIX 0.57
- MACD
- EMO -0.01
- NRIX -0.03
- Stochastic Oscillator
- EMO 38.39
- NRIX 39.08
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.